Table 3.
Significantly affected canonical pathways after Gulf War insult. Green, negative fold changes indicate downregulation. Red, positive fold changes indicate upregulation.
| Ingenuity Canonical Pathways | −log(p-value) | Ratio | Molecules |
|---|---|---|---|
| Protein Ubiquitination Pathway | 4.08 | 0.033 | B2m, Dnaja1, Dnajb4, Hba-a2, Hsp90aa1, Hsp90b1, Hspa4l, Hspa5, Ube2q2 |
| Aldosterone Signaling in Epithelial Cells | 4.07 | 0.0443 | Dnaja1, Dnajb4, Hsp90aa1, Hsp90b1, Hspa4l, Hspa5, Plcb1 |
| Hypoxia Signaling in the Cardiovascular System | 3.9 | 0.0676 | Hsp90aa1, Hsp90b1, Nfkbia, Pten, Ube2q2 |
| Mitotic Roles of Polo-Like Kinase | 3.03 | 0.0606 | Hsp90aa1, Hsp90b1, Slk, Smc3 |
| Prostate Cancer Signaling | 2.51 | 0.044 | Hsp90aa1, Hsp90b1, Nfkbia, Pten |
| Unfolded protein response | 2.23 | 0.0536 | Hsp90b1, Hspa5, Srebf1 |
| Role of PKR in Interferon Induction and Antiviral Response | 2.13 | 0.0342 | Hsp90aa1, Hsp90b1, Hspa5, Nfkbia |
| Endoplasmic Reticulum Stress Pathway | 2.08 | 0.0952 | Hsp90b1, Hspa5 |
| LXR/RXR Activation | 2.08 | 0.0331 | Apod, Pltp, Srebf1, Trf |
| FXR/RXR Activation | 2.02 | 0.0317 | Apod, Pltp, Srebf1, Trf |
| TCA Cycle II (Eukaryotic) | 1.97 | 0.0833 | Dld, Sucla2 |
| Glutamate Dependent Acid Resistance | 1.88 | 0.5 | Gad2 |
| EIF2 Signaling | 1.79 | 0.0223 | Eif3a, Eif5, Eif5b, Hspa5, Srebf1 |
| Gαq Signaling | 1.69 | 0.0253 | Chrm3, Nfkbia, Plcb1, Rhog |
| Cytotoxic T Lymphocyte-mediated Apoptosis of Target Cells | 1.68 | 0.0588 | B2m, Hba-a2 |
| eNOS Signaling | 1.68 | 0.0252 | Chrm3, Hsp90aa1, Hsp90b1, Hspa5 |
| 0X40 Signaling Pathway | 1.67 | 0.0333 | B2m, Hba-a2, Nfkbia |
| Regulation of Actin-based Motility by Rho | 1.62 | 0.0319 | Gsn, Pak3, Rhog |
| CXCR4 Signaling | 1.61 | 0.024 | Egr1, Pak3, Plcb1, Rhog |
| GABA Receptor Signaling | 1.61 | 0.0316 | Gabra2, Gabrb1, Gad2 |
| Neuregulin Signaling | 1.6 | 0.0312 | Hsp90aa1, Hsp90b1, Pten |
| Branched-chain α-keto acid Dehydrogenase Complex | 1.59 | 0.25 | Dld |
| Antigen Presentation Pathway | 1.57 | 0.0513 | B2m, Hba-a2 |
| Nitric Oxide Signaling in the Cardiovascular System | 1.56 | 0.0303 | Hsp90aa1, Hsp90b1, Pde1A |
| PI3K/AKT Signaling | 1.55 | 0.0229 | Hsp90aa1, Hsp90b1, Nfkbia, Pten |
| Sumoylation Pathway | 1.52 | 0.0291 | Nfkbia, Rhog, Senp6 |
| PPAR Signaling | 1.51 | 0.0288 | Hsp90aa1, Hsp90b1, Nfkbia |
| 2-ketoglutarate Dehydrogenase Complex | 1.49 | 0.2 | Dld |
| 2-oxobutanoate Degradation I | 1.49 | 0.2 | Dld |
| Glutamate Degradation III (via 4-aminobutyrate) | 1.49 | 0.2 | Gad2 |
| BAG2 Signaling Pathway | 1.49 | 0.0465 | Hsp90aa1, Hspa5 |
| Dendritic Cell Maturation | 1.49 | 0.0219 | B2m, Hba-a2, Nfkbia, Plcb1 |
| PD-1, PD-L1 cancer immunotherapy pathway | 1.49 | 0.0283 | B2m, Hba-a2, Pten |
| G-Protein Coupled Receptor Signaling | 1.47 | 0.0184 | Chrm3, Cnr1, Nfkbia, Pde1A, Plcb1 |
| Antioxidant Action of Vitamin C | 1.45 | 0.0275 | Nfkbia, Plcb1, Selenot |
| PPARα/RXRα Activation | 1.44 | 0.0211 | Hsp90aa1, Hsp90b1, Nfkbia, Plcb1 |
| iCOS-iCOSL Signaling in T Helper Cells | 1.44 | 0.027 | Hba-a2, Nfkbia, Pten |
| Type I Diabetes Mellitus Signaling | 1.44 | 0.027 | Gad2, Hba-a2, Nfkbia |
| Glycine Cleavage Complex | 1.41 | 0.167 | Dld |
| Natural Killer Cell Signaling | 1.39 | 0.0203 | B2m, Hba-a2, Hspa5, Pak3 |
| Role of Tissue Factor in Cancer | 1.38 | 0.0256 | Egr1, Plcb1, Pten |
| TNFR1 Signaling | 1.37 | 0.04 | Nfkbia, Pak3 |
| Thioredoxin Pathway | 1.35 | 0.143 | Selenot |
| Acetyl-CoA Biosynthesis I (Pyruvate Dehydrogenase Complex) | 1.35 | 0.143 | Dld |
| Neuroinflammation Signaling Pathway | 1.32 | 0.0167 | B2m, Gabra2, Gabrb1, Gad2, Hba-a2 |